 Data from Phase 3 trial for Nirogacestat in treating desmoid tumors and Phase 2 combination trial with anti-BCMA antibody Blenrep in relapsedrefractory multiple myeloma is expected in mid-year. The company has multiple partnerships including with Pfizer, GlaxoSmithKline, Janssen, Seattle Biosciences, Allogene, etc. to combine Nirogacestat with their anti-BCMA therapies. 